LONG-TERM EFFECTIVENESS OF ANTIFIBROTIC DRUGS IN PULMONARY FIBROSIS

Pulmonary fibrosis (PF) is a progressive and life-threatening lung disease characterized by excessive deposition of extracellular matrix, leading to irreversible scarring and impaired respiratory function. Antifibrotic drugs, such as pirfenidone and nintedanib, have emerged as standard therapies aimed at slowing disease progression. Recent studies demonstrate that long-term use of these agents can reduce the decline in lung function, decrease hospitalization rates, and improve overall survival [1,2]. Despite these benefits, challenges remain, including adverse effects, patient adherence, and variability in therapeutic response. Understanding the long-term effectiveness and safety profile of antifibrotic therapy is crucial for optimizing patient management and improving quality of life in PF patients [3,4].